Healio: Early data shows new treatment effective for pediatric Hodgkin lymphoma patients
UC expert presents clinical trial data at ASCO conference
A new combination treatment for patients with advanced-stage Hodgkin lymphoma is safe and effective in pediatric patients, according to early new clinical trial data.
Robin E. Norris, MD, associate professor in the University of Cincinnati Department of Pediatrics in the College of Medicine and director of clinical research for oncology and co-director of the young adult oncology program at Cincinnati Children's Hospital Medical Center, presented updated data from an ongoing phase 1/phase 2 clinical trial of a new combination treatment at the American Society of Clinical Oncology Annual Meeting in Chicago last week. The presentation was highlighted in a recent article by Healio.
The trial is studying the effectiveness of a drug called brentuximab vedotin, a combination immunotherapy and chemotherapy agent, with other chemotherapy regimens.
The drug has been FDA approved as a first-line therapy for adults, and the clinical trial has shown safety and effectiveness so far with patients aged 5-18.
“These safety and efficacy data are consistent with those seen in adult patients,” Norris said. “These findings support the use of brentuximab plus AVD as a reasonable option for pediatric patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma."
Featured photo at top of human lymphoma tumor cells courtesy of the National Cancer Institute.
Related Stories
UC celebrates record graduating class at commencement
April 25, 2024
UC celebrated its doctoral hooding and master's recognition ceremony at Fifth Third Arena as part of its three-day commencement for the largest graduating class in university history.
2024 Daniel Drake Medals to be awarded April 27
April 24, 2024
The UC College of Medicine will award three people with 2024 Daniel Drake Medals April 27.
The graduating class of 2024 shares creative works across 15...
April 24, 2024
DAAP’s Graduating Class of 2024 shares creative works across 15 interdisciplinary degree programs at DAAPworks.